Amgen autoimmune drug meets main goal in late-stage trial
Amgen said its experimental autoimmune drug met the main goal of reducing disease activity in a late-stage trial, with shares up 4% in morning trading.
Amgen said on Tuesday its experimental drug for an autoimmune disease that attacks the body’s moisture-producing glands met the main goal of reducing disease activity in a late-stage trial, sending its shares up 4% in morning trading.